Forty-six client-owned dogs with an established diagnosis of hepatobiliary disease and stored serum samples and eleven client-owned healthy control Labrador Retrievers.
Medical records of dogs with parenchymal, biliary, vascular, or neoplastic hepatobiliary diseases and control dogs were reviewed.
Concentrations of miR-21, miR-122, miR-126, miR-148a, miR-200c, and miR-222 were quantified in serum by real-time polymerase chain reaction.
No different microRNA concentrations were found in the adenoma and congenital portosystemic shunt groups.
In all other diseases, miR-122 concentrations were elevated with the highest concentration in the mucocele group (267-fold, CI: 40–1,768, P < .001).
In dogs with biliary diseases, miR-21 and miR-222 were only increased in dogs with mucoceles (26-fold, CI: 5–141, P = .005 and 13-fold, CI: 2–70, P = .025, respectively).
Uniquely increased microRNAs were found in the hepatocellular carcinoma group (miR-200c, 35-fold increase, CI: 3–382, P = .035) and the chronic hepatitis group (miR-126, 22-fold increase, CI: 5–91, P = .002).
A microRNA panel consisting of miR-21, miR-122, miR-126, miR-200c, and miR-222 can distinguish between parenchymal, biliary, and neoplastic hepatobiliary diseases.
Serum microRNA profiling is a promising new tool that might be a valuable addition to conventional diagnostics to help diagnose various hepatobiliary diseases in dogs.
Source: Dirksen, K., Verzijl, T., Grinwis, G.C., Favier, R.P., Penning, L.C., Burgener, I.A., van der Laan, L.J., Fieten, H. and Spee, B. (2016), Use of Serum MicroRNAs as Biomarker for Hepatobiliary Diseases in Dogs. Journal of Veterinary Internal Medicine, 30: 1816–1823. doi: 10.1111/jvim.14602
|
